( NYSE:KV.B, NYSE:KV.A )

News from K-V Pharmaceutical Company A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

May 09, 2014, 09:00 ET Pharmaceutical Executive Paul Williams Joins K-V Pharmaceutical Company as Head of Women's Healthcare Division

 Today, K-V Pharmaceutical Company ("KV") announced that Paul Williams – a seasoned executive with extensive experience in both neonatal...


Feb 21, 2014, 09:00 ET K-V Pharmaceutical Company Appoints Healthcare Veteran, Gregg Raybuck, to Lead New Maternal Health Division

K-V Pharmaceutical Company ("KV") announced today that Gregg Raybuck, a healthcare veteran with extensive experience in women's and children's...


Nov 05, 2013, 09:00 ET KV Pharmaceutical Company Completes New Board with Appointment of Former Johnson & Johnson Executive

 K-V Pharmaceutical Company ("KV") today announced the appointment of Janet Vergis to its Board of Directors.  Ms. Vergis currently serves...


Oct 11, 2013, 09:00 ET KV Pharmaceutical Company Appoints Two New Board Members

K-V Pharmaceutical Company ("KV") today announced the appointment of two new members to its Board of Directors: Gregory...


Oct 03, 2013, 08:56 ET KV Pharmaceutical Company Appoints Former Wyeth Pharmaceuticals President, Joe Mahady to Chairman of the Board

 K-V Pharmaceutical Company ("KV") today announced the appointment of Joseph M. Mahady as Chairman of its Board of Directors.  Previously,...


Sep 16, 2013, 10:26 ET KV Pharmaceutical Company Completes Reorganization And Successfully Emerges From Chapter 11 With $375 Million Recapitalization

 K-V Pharmaceutical Company ("KV") today announced that its plan of reorganization (the "Plan") has become effective and that it has...


Dec 28, 2012, 12:43 ET K-V Pharmaceutical Receives Court Approval of Hologic Settlement

K-V Pharmaceutical Company ("K-V" or "the Company") today announced that the U. S. Bankruptcy Court for the Southern District of New York, the...


Dec 12, 2012, 18:39 ET K-V Pharmaceutical Secures Commitment for $85 Million Loan, Reaches Agreement with Senior Noteholders on Principal Terms of Plan of Reorganization

K-V Pharmaceutical Company ("K-V" or "the Company") today announced that it has received a commitment from lenders led by an affiliate of Silver...


Aug 10, 2012, 08:00 ET K-V Pharmaceutical Use of Cash Collateral Approved by U. S. Bankruptcy Court

 K-V Pharmaceutical Company ("K-V" or "the Company") announced that the U.S. Bankruptcy Court for the Southern District of New York, the...


Aug 08, 2012, 11:09 ET K-V Pharmaceutical "First Day" Motions Approved by U.S. Bankruptcy Court

K-V Pharmaceutical Company ("K-V" or "the Company") today announced that all "First Day" motions presented to the U.S. Bankruptcy Court on August...


Aug 07, 2012, 12:16 ET K-V Pharmaceutical Class A and Class B Common Stock Begin Trading on the OTC Markets

K-V Pharmaceutical Company ("K-V" or "the Company") today announced that its Class A and Class B common shares have begun trading on the OTCQB...


Aug 06, 2012, 07:57 ET K-V Pharmaceutical Announces Planned Transition of Trading of Class A and Class B Common Shares to the OTC Markets

 K-V Pharmaceutical Company (NYSE: KVa / KVb) ("K-V" or "the Company") today announced that its Class A and Class B common shares may be...


Aug 04, 2012, 00:56 ET K-V Pharmaceutical Company Files Voluntary Petitions for Reorganization to Restructure Financial Obligations

 K-V Pharmaceutical Company (NYSE: KVa/ KVb) ("K-V" or "the Company") and certain of its domestic subsidiaries today filed voluntary Chapter 11...


Jul 20, 2012, 16:05 ET K-V Pharmaceutical Company Announces Additional Notification from NYSE Regarding Listing Criteria

 K-V Pharmaceutical Company (NYSE: KVa/ KVb) ("the Company") today announced that on July 16, 2012 it was notified by the New York Stock...


Jul 02, 2012, 09:15 ET FDA Issues Further Guidance About Makena®

 K-V Pharmaceutical Company (the "Company") (NYSE:  KV.A/KV.B) today addressed the additional guidance provided by the U.S. Food and Drug...


Jun 29, 2012, 18:51 ET K-V Pharmaceutical Company Announces Notification from NYSE Regarding Listing Criteria

 K-V Pharmaceutical Company (NYSE: KVa/ KVb) ("the Company") today announced that on June 26, 2012 it was notified by the New York Stock...


Jun 18, 2012, 09:14 ET FDA and CMS Issue Important Updates on Makena®

 K-V Pharmaceutical Company ("the Company") (NYSE: KV.A/KV.B) announced today that the U.S. Food and Drug Administration (FDA) and the Centers...


May 25, 2012, 16:15 ET K-V Pharmaceutical Company States That Its Policy is Not to Comment on Unusual Market Activity

 K-V Pharmaceutical Company (the "Company") (NYSE: KVa/KVb) today announced that in view of the unusual market activity in the Company's...


Apr 12, 2012, 16:18 ET K-V Pharmaceutical Company to Present at Imperial Capital 2012 Healthcare Investor Forum

 K-V Pharmaceutical Company (the "Company") (NYSE: KVa/KVb) today announced that Greg Divis, President and CEO, and Tom McHugh, Chief Financial...


Apr 02, 2012, 09:01 ET K-V Pharmaceutical Company to Present at Needham & Company 11th Annual Healthcare Conference

 K-V Pharmaceutical Company (the "Company") (NYSE:  KVa/KVb) today announced that Thomas McHugh, Chief Financial Officer, will present at...


Feb 09, 2012, 07:30 ET K-V Pharmaceutical Announces Updated Makena® Performance Metrics and Investor Conference Call

 K-V Pharmaceutical Company (the "Company") (NYSE:  KVa/KVb) today reported updated performance metrics for...


Dec 07, 2011, 09:16 ET K-V Pharmaceutical Company Comments on Recent Settlement With the Department of Justice

K-V Pharmaceutical Company (NYSE: KV.A/ KV.B) (the "Company" or "K-V"), today commented on the settlement of false claims allegations with the U.S....


Nov 08, 2011, 17:45 ET K-V Pharmaceutical Announces Updated Makena® Performance Metrics

K-V Pharmaceutical Company (NYSE: KV.A/ KV.B) (the "Company" or "K-V"), today reported updated performance metrics for Makena®, the only U.S....


Oct 13, 2011, 11:31 ET K-V Pharmaceutical Comments on ACOG and SMFM Information Update Regarding 17-Alpha Hydroxyprogesterone Caproate - FDA-Approved Makena™ and Compounded 17P

In the news release, K-V Pharmaceutical Comments on ACOG and SMFM Information Update Regarding Hydroxyprogesterone Caproate - FDA-Approved...


Sep 28, 2011, 16:15 ET K-V Pharmaceutical Company to Present at Imperial Capital's 5th Annual Global Opportunities Conference

K-V Pharmaceutical Company (the "Company") (NYSE:  KVa/KVb) today announced that Thomas McHugh, Chief Financial Officer, will present at...